Nykode Therapeutics ASA (NYKDNOK)

Stockholm


Symbol		Exchange		Currency
NYKD	·	Oslo	·	NOK	Real-time
NYKDNOK	·	Stockholm	·	NOK	Real-time

Currency in NOK

1.85

0.00(0.00%)

Closed·01/07

Fair Value

Unlock Value

Day's Range

1.85

52 wk Range

1.67

2.90

NYKDNOK Financial Summary

A brief financial summary of Nykode Therapeutics ASA as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Key Ratios

P/E Ratio-2.08

Price/Book0.4

Debt / Equity2.45%

Return on Equity-17.3%

Dividend Yield0.00%

EBITDA-47.59M

Fair ValueUnlock

Fair Value UpsideUnlock

Statements Highlights

Period Ending:

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

Income Statement

Total Revenues

aa.aa

1,850.21

314.98

88.45

135.03

104.09

Gross Profit

aa.aa

1,850.21

314.98

88.45

135.03

104.09

Operating Income

aa.aa

1,529.14

-94.89

-520.74

-588.67

-549.32

Net Income

aa.aa

1,284.75

-82.91

-418.73

-356.29

-441.23

Balance Sheet

Total Assets

aa.aa

1,973.16

2,338.67

2,169.7

2,109.98

1,744.42

Total Current Liabilities

aa.aa

113.07

276.24

381.92

208.86

103.42

Total Equity

aa.aa

1,534.16

1,708.98

1,538.23

1,735.73

1,548.17

Cash Flow

Levered Free Cash Flow

aa.aa

103.92

6.38

-8.6

-49.62

-34.3

Cash from Operations

aa.aa

180.27

1.16

-20.69

-96.62

-51.22

Cash from Investing

aa.aa

-6.02

10.75

11.05

7.04

6.93

Cash from Financing

aa.aa

-0.29

20.44

0.36

44.59

-1.4

Net Change in Cash

aa.aa

173.69

32.38

-9.85

-43.78

-47.2

* In Millions of NOK (except for per share items)

Earnings

Latest Release

Apr 29, 2025

EPS / Forecast

-0.02 / --

Revenue / Forecast

6.89M / --

EPS Revisions

Unlock

Last 90 days

FAQ

What were Nykode Therapeutics ASA's earnings for the latest quarter?

The Nykode Therapeutics ASA EPS (TTM) is -0.08. Nykode Therapeutics ASA reported sales of 0.14, net income of -1.44, and EPS of -0.02 for the latest quarter.

What was Nykode Therapeutics ASA's net income for the latest quarter?

Nykode Therapeutics ASA's net income for the latest quarter was -1.44.

How did Nykode Therapeutics ASA's performance compare year-over-year in the latest quarter?

The company's revenue moved from 6.89 in the previous quarter to 0.14 in the latest quarter, and net income moved from -6.76 to -1.44 compared to the previous quarter.

What is Nykode Therapeutics ASA's net profit margin on a TTM basis?

Nykode Therapeutics ASA's trailing twelve months (TTM) net profit margin is -423.90%.

How does Nykode Therapeutics ASA's debt to equity ratio compare to industry standards?

Nykode Therapeutics ASA's total debt-to-equity ratio is 2.45%.

What is Nykode Therapeutics ASA's return on investment on a TTM basis?

Nykode Therapeutics ASA's trailing twelve months (TTM) return on investment (ROI) is -17.30%.

Did Nykode Therapeutics ASA gain or lose cash last quarter?

In the latest quarter, Nykode Therapeutics ASA's net change in cash was -9.16 million.

What were Nykode Therapeutics ASA's total assets and liabilities in the latest quarter?

As of the latest quarter, Nykode Therapeutics ASA reported total assets of 146.61 million and total liabilities of 6.42 million.

How has Nykode Therapeutics ASA's total revenue grown this year?

Nykode Therapeutics ASA's total revenue was 6.89 in the previous quarter and 0.14 in the latest quarter.

What is Nykode Therapeutics ASA's gross margin on a TTM basis?

Nykode Therapeutics ASA's trailing twelve months (TTM) gross margin is 100.00%.

What was Nykode Therapeutics ASA's revenue per share for the latest quarter?

Nykode Therapeutics ASA's revenue per share for the latest quarter was 0.76.

NSE 30

4,932.39

+44.05

+0.90%

NSE All Share

134,452.94

+1,252.96

+0.94%

US 30

44,899.80

+205.7

+0.46%

US 500

6,393.40

+30.0

+0.47%

FTSE 100

9,120.31

-18.06

-0.20%

DAX

24,217.50

-78.43

-0.32%

South Africa Top 40

91,303.40

-954.88

-1.04%

Market Movers

Name	Last	Chg. %	Vol.
Access Holdings	27.70	-2.81%	42.42M
Guaranty Trust Holding	94.00	-0.11%	28.71M
Zenith Bank	74.00	+1.09%	16.96M
MTN Nigeria	400.00	+1.27%	3.44M
Okomu Oil Palm	998.00	+5.05%	2.58M
Presco	1,550.00	+7.68%	900.61K
Seplat Petroleum	5,450.00	0.00%	337.85K

Name	Last	Chg. %	Vol.
Champion Brew	12.32	+10.00%	1.69M
Unilever Nigeria	68.20	+10.00%	1.19M
Ikeja	23.100	+10.00%	3.01M
Nigerian Enamelware PLC	27.00	+9.98%	110.03K
Initiates	16.13	+9.95%	3.53M
Academy Press	9.31	+9.92%	2.12M
Prestige	1.23	+9.82%	13.85M

Name	Last	Chg. %	Vol.
Tripple Gee and Co	3.51	-10.00%	469.29K
Tantalizers	2.46	-8.55%	32.20M
Sunu Assurances	4.64	-6.64%	18.84M
ETI	32.00	-5.88%	4.55M
Neimeth	6.50	-4.55%	7.07M
Rtbriscoe	3.58	-4.53%	5.90M
Linkassure	1.50	-3.23%	894.80K

Trending Stocks

Name	Last	Chg. %	Vol.
Champion Brew	12.32	+10.00%	1.69M
Ellah Lakes	9.80	-2.00%	26.34M
Oando Plc	60.05	+4.62%	14.40M
Lafarge Africa	125.05	+2.08%	5.85M
Okomu Oil Palm	998.00	+5.05%	2.58M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaaaaaaa	5,450.00	+29.88%	7,078.46
Aaaaaaaaa	66.50	+28.33%	85.34
Aaa Aaaaaaaaa	400.00	+10.33%	441.32

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Nykode Therapeutics ASA (NYKDNOK)

NYKDNOK Financial Summary

Key Ratios

Statements Highlights

Earnings

FAQ

What were Nykode Therapeutics ASA's earnings for the latest quarter?

What was Nykode Therapeutics ASA's net income for the latest quarter?

How did Nykode Therapeutics ASA's performance compare year-over-year in the latest quarter?

What is Nykode Therapeutics ASA's net profit margin on a TTM basis?

How does Nykode Therapeutics ASA's debt to equity ratio compare to industry standards?

What is Nykode Therapeutics ASA's return on investment on a TTM basis?

Did Nykode Therapeutics ASA gain or lose cash last quarter?

What were Nykode Therapeutics ASA's total assets and liabilities in the latest quarter?

How has Nykode Therapeutics ASA's total revenue grown this year?

What is Nykode Therapeutics ASA's gross margin on a TTM basis?

What was Nykode Therapeutics ASA's revenue per share for the latest quarter?

Trending Stocks